Display options
Cite
Weng Z, Spies N, Zhu SX, et al. Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia. Genome Med. 2015;7(1):28doi: 10.1186/s13073-015-0146-2.
Weng, Z., Spies, N., Zhu, S. X., Newburger, D. E., Kashef-Haghighi, D., Batzoglou, S., Sidow, A., & West, R. B. (2015). Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia. Genome medicine, 7(1), 28. https://doi.org/10.1186/s13073-015-0146-2
Weng, Ziming, et al. "Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia." Genome medicine vol. 7,1 (2015): 28. doi: https://doi.org/10.1186/s13073-015-0146-2
Weng Z, Spies N, Zhu SX, Newburger DE, Kashef-Haghighi D, Batzoglou S, Sidow A, West RB. Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia. Genome Med. 2015 Apr 09;7(1):28. doi: 10.1186/s13073-015-0146-2. eCollection 2015. PMID: 25918554; PMCID: PMC4410742.
Copy Download .nbib Format: NLM
Share it on

Genome Med. 2015 Apr 09;7(1):28. doi: 10.1186/s13073-015-0146-2. eCollection 2015.

Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia.

Genome medicine

Ziming Weng, Noah Spies, Shirley X Zhu, Daniel E Newburger, Dorna Kashef-Haghighi, Serafim Batzoglou, Arend Sidow, Robert B West

Affiliations

  1. Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305 USA ; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305 USA.
  2. Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305 USA.
  3. Biomedical Informatics Training Program, Stanford University, Stanford, CA 94305 USA.
  4. Department of Computer Science, Stanford University, Stanford, CA 94305 USA.

PMID: 25918554 PMCID: PMC4410742 DOI: 10.1186/s13073-015-0146-2

Abstract

BACKGROUND: All cells in an individual are related to one another by a bifurcating lineage tree, in which each node is an ancestral cell that divided into two, each branch connects two nodes, and the root is the zygote. When a somatic mutation occurs in an ancestral cell, all its descendants carry the mutation, which can then serve as a lineage marker for the phylogenetic reconstruction of tumor progression. Using this concept, we investigate cell lineage relationships and genetic heterogeneity of pre-invasive neoplasias compared to invasive carcinomas.

METHODS: We deeply sequenced over a thousand phylogenetically informative somatic variants in 66 morphologically independent samples from six patients that represent a spectrum of normal, early neoplasia, carcinoma in situ, and invasive carcinoma. For each patient, we obtained a highly resolved lineage tree that establishes the phylogenetic relationships among the pre-invasive lesions and with the invasive carcinoma.

RESULTS: The trees reveal lineage heterogeneity of pre-invasive lesions, both within the same lesion, and between histologically similar ones. On the basis of the lineage trees, we identified a large number of independent recurrences of PIK3CA H1047 mutations in separate lesions in four of the six patients, often separate from the diagnostic carcinoma.

CONCLUSIONS: Our analyses demonstrate that multi-sample phylogenetic inference provides insights on the origin of driver mutations, lineage heterogeneity of neoplastic proliferations, and the relationship of genomically aberrant neoplasias with the primary tumors. PIK3CA driver mutations may be comparatively benign inducers of cellular proliferation.

References

  1. Mod Pathol. 2012 Jul;25(7):930-7 - PubMed
  2. Cancer Res. 2011 Jul 1;71(13):4344-51 - PubMed
  3. Breast Cancer Res Treat. 2010 Apr;120(2):409-18 - PubMed
  4. Cancer Res. 2012 Oct 1;72(19):4875-82 - PubMed
  5. Nature. 2010 Oct 28;467(7319):1109-13 - PubMed
  6. Mod Pathol. 2014 Jun;27(6):869-74 - PubMed
  7. Genome Biol. 2014 May 23;15(5):R71 - PubMed
  8. Nature. 2011 Apr 7;472(7341):90-4 - PubMed
  9. J Pathol. 2012 May;227(1):42-52 - PubMed
  10. Cancer Res. 2010 Jul 15;70(14):5674-8 - PubMed
  11. Nature. 2010 Oct 28;467(7319):1114-7 - PubMed
  12. Int J Oncol. 2006 Oct;29(4):935-45 - PubMed
  13. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  14. J Clin Invest. 2011 Oct;121(10):3810-8 - PubMed
  15. Nature. 2013 Jul 11;499(7457):214-8 - PubMed
  16. Nature. 2012 Apr 04;486(7403):395-9 - PubMed
  17. N Engl J Med. 2012 Nov 22;367 (21):1998-2005 - PubMed
  18. Genome Res. 2013 Jul;23(7):1097-108 - PubMed
  19. Genome Biol. 2009;10(3):R25 - PubMed
  20. Clin Cancer Res. 2009 Aug 15;15(16):5017-9 - PubMed
  21. Sci Am. 2007 Mar;296(3):50-7 - PubMed
  22. J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54 - PubMed
  23. Nature. 2012 Apr 18;486(7403):346-52 - PubMed
  24. Nat Genet. 2014 Mar;46(3):225-33 - PubMed
  25. Nucleic Acids Res. 2012 Aug;40(15):e115 - PubMed
  26. Science. 2012 Apr 20;336(6079):304-5 - PubMed
  27. Mod Pathol. 2014 May;27(5):740-50 - PubMed
  28. Br J Cancer. 2004 Jul 19;91(2):355-8 - PubMed
  29. Nat Biotechnol. 2013 Mar;31(3):213-9 - PubMed

Publication Types

Grant support